Human Acute Lymphoid Leukemia Peripheral Blood CD19+ B Cells (Relapsed/Refractory)

Description

Human Acute Lymphoid Leukemia CD19+ B cells are isolated from peripheral blood of adult patients with relapsed or refractory B-cell acute lymphoid leukemia (B-ALL) via positive immunomagnetic CD19 MicroBead selection of PBMCs, enriching malignant B-cell populations. As primary cells, they are not immortalized and have limited proliferative capacity, viable for short-term culture. Morphologically, they display blast-like features with a high nuclear-to-cytoplasmic ratio. Functionally, they support studies of aberrant B-cell receptor signaling, glucocorticoid resistance, immune evasion in relapsed ALL B cells, and CD19+ B cell depletion strategies in leukemia, as well as leukemic proliferation in relapsed B-ALL. To ensure the quality of these primary cells, repeated freeze-thaw cycles are not recommended due to the fragile nature of these cells. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.